Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Current Management of Retinal Vascular Diseases: Optimizing Treatment Protocol

By: Rishi P. Singh, MD, moderator; Jeffrey S. Heier, MD; Dante Pieramici, MD; Jonathan Prenner, MD

This course has expired. You can still review the content but course credit is no longer available.

Supplement Credits: 1

A CME activity provided by Evolve Medical Education LLC and distributed with New Retina MD and Retina Today.

CONTENT SOURCE
This continuing medical education (CME) activity captures content from roundtable discussion held in August 2016 in San Francisco, Ca.

TARGET AUDIENCE
This certified CME activity is designed for retina specialists and general ophthalmologists involved in the management of patients with retinal disease.

Expiration Date: Thursday, November 30, 2017
Release Date: November 2016

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Understand the most recent monotherapy and combination therapy clinical study evidence using available anti-VEGF, steroid, and photodynamic therapies for common retinal diseases, including AMD, RVO, and DME
  • Discuss the outcomes of pivotal studies in AMD, RVO, and DME as well as how study results may differ from real-world dosing methods
  • Develop plans to initiate treatment for conditions such as AMD, RVO, and DME using anti-VEGF agents as well as better understand when to change therapeutic strategies and/or therapeutic classes
  • Evaluate practice flow to determine the most efficient patient experience
  • Develop plans to reduce reimbursement denials

Accreditation and Designation Statement

ACCREDITATION STATEMENT

Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

FACULTY CREDENTIALS

Rishi P. Singh, MD, moderator
Cole Eye Institute, Cleveland Clinic
Cleveland, Ohio

Jeffrey S. Heier, MD
Tufts University/Ophthalmic Consultants of Boston
Boston, Massachusetts

Dante Pieramici, MD
California Retina Consultants and Research Foundation
Santa Barbara, California

Jonathan Prenner, MD
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey

DISCLOSURE POLICY STATEMENT

It is the policy of Evolve Medical Education LLC that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve Medical Education LLC has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty members have the following financial relationships with commercial interests:

Rishi P. Singh, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Genentech; Regeneron Pharmaceuticals; and ThromboGenics NV. Grant/Research Support: Alcon; Genentech; and Regeneron Pharmaceuticals.

Jeffrey S. Heier, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Acucela; Aerpio; Alcon; Allergan; Bausch + Lomb; Bayer Healthcare Pharmaceuticals; Dutch Ophthalmic; Endo Optiks; Forsight Labs; Genentech; Genzyme/Sanofi; Heidelberg; Kala Rx; Chengdu Kanghong Pharmaceuticals Group; Liquidia; Merz; Nicox; Novartis; Notal Vision Ltd; Ohr Pharmaceuticals; Oraya; QLT; Regeneron Pharmaceuticals; Sequenom; Stealth Peptide; Thrombogenics, NV; and Xcovery. Grant/Research Support: Allergan; Bayer Healthcare Pharmaceuticals; Genentech; Genzyme/Sanofi; GlaxoSmithKline; Lpath; Notal Vision Ltd; Ohr Pharmaceuticals; Ophthotech Corporation; and Regeneron Pharmaceuticals.

Dante Pieramici, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allergan; Genentech; and ThromboGenics NV. Grant/Research Support: Alcon; Alimera Sciences; Allergan; Genentech; Ophthotech Corporation; and River Vision.

Jonathan Prenner, MD, has had a financial agreement or affiliation during the past year with the following commercial interests

in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; and Regeneron Pharmaceuticals. Stock/Shareholder: Ophthotech Corporation; and PanOptica.

EDITORIAL SUPPORT DISCLOSURE

Cheryl Cavanaugh, MS, director of operations, Evolve Medical Education LLC; Bryan Bechtel, writer; and David Friess, reviewer, have no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, New Retina MD, Retina Today, or Regeneron Pharmaceuticals.

Current Management of Retinal Vascular Diseases: Optimizing Treatment Protocol: SUPPLEMENT

Rishi P. Singh, MD, moderator; Jeffrey S. Heier, MD; Dante Pieramici, MD; Jonathan Prenner, MD

BackNext